Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared With BGF Delivered by MDI HFA in Participants With Chronic Obstructive Pulmonary Disease

NCT06075095 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06075095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared With BGF Delivered by MDI HFA in Participants With Chronic Obstructive Pulmonary Disease
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 11, 2024
Completion date
August 12, 2025
Enrollment
297 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

copd (chronic obstructive pulmonary disease)